Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts

Graceway Pharmaceuticals, LLC511 enrolled

Overview

The purpose of this study is to determine whether imiquimod creams are effective in treating external genital warts (EGW). The secondary objective of this study is to provide information on recurrence of EGW. Additionally the study will also look at any adverse events associated with the use of the creams. External genital and perianal warts are caused by the infection of human papillomavirus or HPV. HPV infection is a sexually transmitted disease (STD). External genital warts look like small flesh-colored, pink, or red growths on or around the external skin of sex organs or perianal area. The warts may look similar to the small parts of a cauliflower or they may be very tiny and difficult to see. They often appear in clusters of three or four, and may grow and spread rapidly. They usually are not painful, although they may cause mild pain, bleeding, and itching.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

511

Conditions

Genital Warts

Interventions

Eligibility

Sex: ALLMin age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: * In good general health * Diagnosis of external genital / perianal warts with at least 2 warts and no more than 30 warts * Negative pregnancy test (for women who are able to become pregnant) Exclusion Criteria: * Women who are pregnant, lactating or planning to become pregnant during the study * Evidence of clinically significant or unstable disease (such as stroke, heart attack) * Have any of the following conditions: HIV infection; current or history of high risk HPV infection (e.g., HPV types 16, 18, etc.); outbreak of herpes genitalia in the wart areas; internal warts requiring or undergoing treatment; dermatological disease (e.g., psoriasis) or skin condition in the wart areas * Have received specific treatments in the treatment area(s) within the designated time period prior to study treatment initiation

Locations (43)

NEA Clinic

Jonesboro, Arkansas, United States

Northern Claifornia Research

Carmichael, California, United States

California State University - Chico

Chico, California, United States

Dermatology Research Associates

Los Angeles, California, United States

Conant Foundation

San Francisco, California, United States

Outcomes

Primary Outcomes

Proportion of Subjects Achieving Complete Clearance of All Warts (Baseline and New) at the End of Study.

The complete clearance was defined as completely cleared all warts including baseline and newly emerged during the study at all anatomic areas.

Time frame: Up to 16 weeks

Secondary Outcomes

Number of Subjects With Any Treatment Related Adverse Reactions (AEs), Any Local Skin Reactions (LSRs), and Number of Subjects Who Took Rest Periods During the Treatment Period

Treatment related defined as "probably related" or "related" by investigator. Local skin reactions (LSRs)were part of the treatment related adverse events and assessed by the investigators. Rest periods defined as temporary interruption of dosing due to intolerable local skin reaction.

Time frame: Up to 16 weeks